Oncological features and prognosis of colorectal cancer in human immunodeficiency virus-positive patients: A retrospective study

Table 5 Oncological characteristics of patients in the two groups

	HIV-positive (n = 24)	HIV-negative (n = 48)	P value
Number of metastatic lymph nodes	1 (0, 3.5)	0 (0, 0)	0.001
Node stage	1 (0, 1.75)	0 (0, 1)	0.005
Harvested lymph nodes	13 (10, 15.75)	14.5 (11.25, 18)	0.223
Size of largest lymph node	0.85 (0.525, 1.45)	0.8 (0.5, 1)	0.318
Metastasis	2 (8.3)	2 (4.2)	0.597
TNM stage	3 (2, 3)	2 (2, 2.75)	0.004
Tumor size (cm)	3.75 (2.5, 5)	4 (3, 5)	0.497
Margin	0	0	NA
MSI	1 (11.1)	1 (6.3)	1
RAS gene mutation	3 (37.5)	13 (76.5)	0.087
BRAF gene mutation	0	1 (5.8)	1
MLH1	14 (82.4)	35 (92.1)	0.359
MSH2	16 (94.1)	37 (97.4)	0.527
MSH6	16 (94.1)	37 (97.4)	0.527
Ki-67 (%)	70 (60, 80)	60 (50, 80)	0.159

Variables are expressed as median (P25, P75) or n (%). HIV: Human immunodeficiency virus; MSI: Microsatellite instability; TNM: Tumor-Node-Metastasis; RAS: Rat sarcoma; BRAF: Serine/threonine protein kinase B-raf; MLH1: MutL homologue 1; MSH: Melanocyte-stimulating hormone; Ki-67: Antigen identified by monoclonal antibody Ki-67; NA: Not available.